What is Lanxess' full-year 2026 EBITDA guidance, and what key factors support its decision to maintain this outlook despite challenging market conditions?

Lanxess maintains its full-year 2026 EBITDA pre-exceptional items guidance of €450 million to €550 million, citing strong second-quarter performance — with sales up 6.5% year-on-year and 13.3% sequentially to €1.56 billion, and EBITDA pre-exceptional items rising 1.3% year-on-year and 61.7% sequentially to €152 million — as well as expected greater contributions from ongoing cost-reduction and efficiency programs in the second half, even though 'there is no sign of a sustained upturn in demand in our core markets' and 'market conditions remain challenging'.

How did Lanxess' specialty additives segment perform in Q2 2026 compared to the prior-year period, and why is this notable relative to other segments?

In Q2 2026, Lanxess' specialty additives segment reported sales of €588 million, up 11.4% year-on-year, and EBITDA pre-exceptional items of €77 million, up 32.8% year-on-year, with EBITDA margin improving to 13.1% from 11% — making it the only segment to deliver strong growth in both sales and EBITDA, unlike the consumer protection segment (EBITDA down 6.9%) and advanced intermediates segment (EBITDA down 20.5%), and underscoring its outperformance amid broad market weakness.

Lanxess maintains full-year outlook despite challenging environment

Aug 7, 2026

Lanxess AG confirmed its full-year 2026 EBITDA guidance of €450-550 million after Q2 sales rose 6.5% year over year. While market conditions remain challenging, the specialty chemicals firm expects cost-reduction programs to improve contributions.

chemweek

2026-08-07

Lanxess maintains full-year outlook despite challenging environment

Lanxess maintains full-year outlook despite challenging environment

FAQ